Search
Search Results
##search.searchResults.foundPlural##
-
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
5161PDF: 3001HTML: 2370 -
How I treat acute and persistent sickle cell pain
2144PDF: 1199HTML: 801 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
3065PDF: 1455HTML: 3741Untitled: 258Untitled: 261Untitled: 220 -
NURSING MANAGEMENT OF HAEMORRHAGIC CYSTITIS IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTRE ITALIAN SURVEY Nursing management of haemorrhagic cystitis
2258PDF: 1138HTML: 330 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1521PDF: 870HTML: 1039 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2999PDF: 1025HTML: 659 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1823PDF: 861HTML: 932jdoe, table 2 infections CML .doc: 253jdoe, table 1 infections CML .doc: 233 -
Severe autoimmune hemolytic anemia in Covid-19 infection Autoimmune hemolytic anemia in Covid-19
3488PDF: 1670HTML: 295 -
LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
1459PDF: 976HTML: 1309fig 1A: 238figure1B: 203 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2296PDF: 924HTML: 381 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3353PDF: 1433HTML: 4166 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2729PDF: 1683HTML: 734 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1273PDF: 821HTML: 1543Figure 1: 263Figure 2: 274 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3303PDF: 1699HTML: 406 -
-
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
1085PDF: 579HTML: 346 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
2021PDF: 1247HTML: 350 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
2787PDF: 1265HTML: 290 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1823PDF: 2065Suppl. Files: 290HTML: 123 -
NEW STRATEGIES FOR STEM CELL MOBILIZATION
2610PDF: 971HTML: 2586







